Literature DB >> 8027665

Heterogeneous spontaneous and interleukin-4-induced nitric oxide production by human monocytes.

G Mautino1, N Paul-Eugène, P Chanez, A M Vignola, J P Kolb, J Bousquet, B Dugas.   

Abstract

The generation of nitric oxide by human monocytes has long been a subject of controversy because of the difficulty of rationalizing this production. In this work we evaluated the capacity of human monocytes to produce nitric oxide (NO) as measured by nitrite (NO2-) release. Resting unstimulated monocytes (2 x 10(6) cells/ml) were found to produce significant amounts of NO2- after 8 to 12 days in culture. This production appeared to be highly heterogeneous. Indeed, approximately, 75% of monocytes from the different donors produced up to 10 microM NO2- and were considered low producers; the last 25% produced higher amounts of NO2- (from 10 to 110 microM) and were considered high producers. In any case the spontaneous production of NO2- by monocytes was overcome in the presence of 1 mM N omega-monomethyl-L-arginine (LNMMA). This inhibitory effect was reversed in the presence of an excess of L-arginine (5 mM), indicating that this process is effectively dependent on L-arginine metabolism. Because interleukin-4 (IL-4) is considered an important NO-regulatory cytokine, its regulatory effect on this spontaneous production of NO was also evaluated. In the presence of a defined dose of IL-4 (1 to 100 ng/ml) the spontaneous production of the high-producing population of monocytes was abrogated, whereas IL-4 stimulated the production by the low-producing population of monocytes, which was suppressed in the presence of LNMMA. The present data indicate that NO production by human monocytes is heterogeneous and that IL-4 can be a potent inducer or inhibitor of this production, suggesting a variability in the activation state of these cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8027665     DOI: 10.1002/jlb.56.1.15

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  8 in total

1.  Dimerization of major histocompatibility complex class I on the surface of THP-1 cells stimulates the expression of inducible nitric oxide synthase and subsequent nitric oxide release.

Authors:  G Bottley; N Fernández
Journal:  Immunology       Date:  2000-08       Impact factor: 7.397

2.  Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B.

Authors:  N Mozaffarian; J W Berman; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Kinetic modelling of the nitric oxide gradient generated in vitro by adherent cells expressing inducible nitric oxide synthase.

Authors:  M Laurent; M Lepoivre; J P Tenu
Journal:  Biochem J       Date:  1996-02-15       Impact factor: 3.857

4.  Role of leukotriene B4 in the interleukin-4-induced human mononuclear phagocyte activation.

Authors:  N Dugas; B Dugas; J P Kolb; K Yamaoka; J F Delfraiss; C Damais
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

5.  Decreased interleukin-4 and increased gamma interferon production by peripheral blood mononuclear cells of patients with Lyme borreliosis.

Authors:  J Oksi; J Savolainen; J Pène; J Bòusquet; P Laippala; M K Viljanen
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

6.  Nonadherent cultures of human monocytes kill Mycobacterium smegmatis, but adherent cultures do not.

Authors:  K Barker; H Fan; C Carroll; G Kaplan; J Barker; W Hellmann; Z A Cohn
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

Review 7.  Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review.

Authors:  J B Weinberg
Journal:  Mol Med       Date:  1998-09       Impact factor: 6.354

8.  Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis.

Authors:  S Nicholson; M da G Bonecini-Almeida; J R Lapa e Silva; C Nathan; Q W Xie; R Mumford; J R Weidner; J Calaycay; J Geng; N Boechat; C Linhares; W Rom; J L Ho
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.